A New Clinic-Genetic Risk Score for Predicting Venous Thromboembolic Events in Cancer Patient

Summary

Venous thromboembolism (VTE) is a common disease in cancer patients and one of the major causes of cancer-associated mortality. Risk for developing VTE increases when cancer patients are receiving chemotherapy. Current risk scores for predicting cancer-associated VTE in ambulatory patients had low/moderate discrimination and clinical sensitivity. These models use clinical and biochemical parameters of the patient.

In the development of VTE genetics play a relevant role. The product Thrombo inCode (TiC) assess VTE risk prediction by using a combination of a genetic risk score (GRS) and clinical parameters from the patient. The investigators hypothesized that the GRS included in TiC combined with clinical parameter some of them associated with cancer could be better predicted by TiC than by current risk scores (Khorana score).

After publishing the primary results in 2018, we have expanded the GRS in a external validation cohort adding gliomas and biliary tract tumors. Also we have incorporated the assessment of D-dimer in order to improve the predictive capability.

Conditions

• Cancer-associated Thrombosis
• Genetic Predisposition

Sponsors & Collaborators

• Servicio de Oncología Médica. HGU Gregorio Marañón. Madrid

  collaborator UNKNOWN

• Unitat de Genòmica de Malalties Complexes. Institut d'Investigació Sant Pau

  collaborator UNKNOWN

• Hospital Universitario La Paz

  collaborator OTHER

• Hospital Universitario Ramon y Cajal

  collaborator OTHER

• Hospital Clinic of Barcelona

  collaborator OTHER

• Hospital Universitario de Fuenlabrada

  collaborator OTHER

• Hospital Universitario Marqués de Valdecilla

  collaborator OTHER

• Complexo Hospitalario de Ourense

  collaborator OTHER

• Complejo Universitario Torrecárdenas, Almería

  collaborator UNKNOWN

• Gendiag

  collaborator INDUSTRY

• Ferrer inCode, S.L.

  collaborator INDUSTRY

• Unitat d'Hemostasia i Trombosi. Hospital de la Santa Creu i Sant Pau

  collaborator UNKNOWN

• LEO Pharma

  collaborator INDUSTRY

• Sociedad Española de Trombosis y Hemostasia (SETH)

  collaborator UNKNOWN

• Sociedad Española de Oncología Médica (SEOM)

  collaborator UNKNOWN

• University Hospital Virgen de las Nieves

  collaborator OTHER

• Hospital Obispo Polanco, Teruel

  collaborator UNKNOWN

• Complejo Hospitalario Universitario de Vigo

  collaborator OTHER

• Hospital General Universitario Elche

  collaborator OTHER

• Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

  collaborator OTHER

• Hospital General de Ciudad Real

  collaborator OTHER

• Andres muñoz

  lead OTHER

Principal Investigators

• Andrés J. Muñoz Martín, MD PhD · Hospital General Universitario Gregorio Marañón

Eligibility

Min Age

18 Years

Max Age

99 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2013-03-31

Primary Completion

2020-12-31

Completion

2021-02-28

Countries

• Spain

Study Locations